These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates. Seifert H Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Blondeau JM; Laskowski R; Bjarnason J; Stewart C Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500 [TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. Jones RN; Pfaller MA; Doern GV Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536 [TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Pontani D; Washton H; Bouchillon S; Johnson J Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Bongaerts GP; Hoogkamp-Korstanje JA Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564 [TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones]. Tali-Maamar H; Tebbal S; Rahal K Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. Malmborg AS; Ahlén S Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030 [TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065 [TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039 [TBL] [Abstract][Full Text] [Related]
18. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071 [TBL] [Abstract][Full Text] [Related]